Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Shaw

Showing results (171-180 of 174) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 174 results.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
British Journal of Cancer|August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumoursRebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
Pageof 18

Showing results (171-180 of 174) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 174 results.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
British Journal of Cancer|August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumoursRebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
Pageof 18